- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00894322
A Study to Examine the Pharmacokinetics, Tolerability, Safety and Efficacy of Exenatide Once Weekly Suspension
September 3, 2015 updated by: AstraZeneca
A Two-Cohort, Single- and Repeat Dose Study to Examine the Pharmacokinetics, Tolerability, and Safety of Ready to Use Exenatide Once Weekly in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus
This study is designed to evaluate the pharmacokinetics, tolerability, and safety of exenatide once weekly suspension in both healthy subjects and in subjects with type 2 diabetes.
The study will also evaluate efficacy in the type 2 diabetes patients.
Development of this exenatide once weekly presentation would eliminate the need to reconstitute the product prior to use.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
65
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Nebraska
-
Lincoln, Nebraska, United States
- Research Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years to 75 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Cohort 1:
- Is 19 to 65 years old
- Has a body mass index (BMI) of 23 kg/m2 to 35 kg/m2, inclusive, at study start
Cohort 2:
- Is 19 to 75 years old
- Has been diagnosed with type 2 diabetes mellitus
- Has HbA1c of 7.1% to 10.0%, inclusive, at study start
- Has a body mass index (BMI) of 25 kg/m2 to 45 kg/m2, inclusive, at study start
- Has been treated with diet and exercise alone or with a stable regimen of metformin, a TZD, or a combination of metformin and a TZD, for a minimum of 2 months prior to study start
Either is not treated with or has been on a stable treatment regimen with any of the following medications for a minimum of 2 months prior to study start:
- Hormone replacement therapy (female subjects)
- Oral contraceptives (female subjects)
- Antihypertensive agents
- Lipid-lowering agents
- Thyroid replacement therapy
- Antidepressant agents
Exclusion Criteria:
Cohort 1:
- Has a personal history of diabetes mellitus (including impaired glucose tolerance, impaired fasting glucose, or gestational diabetes)
- Has received any investigational drug within 30 days (or 5 half-lives of the investigational drug, whichever is greater) prior to study start
- Has ever been exposed to exenatide (BYETTA, exenatide once weekly, or any other formulation of exenatide) or any GLP 1 analog
Cohort 2:
- Has received any investigational drug within 30 days (or 5 half-lives of the investigational drug, whichever is greater) prior to study start
- Has ever been exposed to exenatide (BYETTA, exenatide once weekly, or any other formulation of exenatide) or any GLP 1 analog
Has been treated, is currently being treated, or is expected to require or undergo treatment with any of the following treatment-excluded medications:
- Any DPP-4 inhibitor or sulfonylurea (SU) within 3 months prior to study start
- Alpha glucosidase inhibitor, meglitinide, nateglinide, or pramlintide (SYMLIN®) within 30 days prior to study start
- Insulin within 2 weeks prior to study start or for more than 1 week within 3 months prior to study start
- Systemic corticosteroids by oral, intravenous, or intramuscular route; or potent, inhaled, or intrapulmonary (including ADVAIR®) steroids known to have a high rate of systemic absorption
- Prescription or over-the-counter weight loss medications within 3 months prior to study start
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Cohort 1: Healthy Participants
A single 10-mg dose of exenatide once weekly suspension given to healthy participants via 3 subcutaneous (SC) injections at Day 1.
|
subcutaneous injection, 10.0 mg, single injection
subcutaneous injection, 2.0 mg, once a week for 12 weeks
|
EXPERIMENTAL: Cohort 2: Diabetes Participants
On Day 1, participants with type 2 diabetes mellitus treated with diet and exercise alone or with a stable regimen of metformin, thiazolidinedione (TZD), or a combination of metformin or TZD were randomized to receive weekly injections of exenatide suspension for 12 weeks.
|
subcutaneous injection, 10.0 mg, single injection
subcutaneous injection, 2.0 mg, once a week for 12 weeks
|
PLACEBO_COMPARATOR: Cohort 2: Diabetes Participants Placebo
On Day 1, participants with type 2 diabetes mellitus treated with diet and exercise alone or with a stable regimen of metformin, thiazolidinedione (TZD), or a combination of metformin or TZD were randomized to receive weekly injections of medium-chain triglycerides (MCT)-diluent placebo for 12 weeks.
|
subcutaneous injection, volume equivalent to Cohort 2 experimental intervention, once a week for 12 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area Under the Curve (AUC) for Single Dose of 10 mg Exenatide (Cohort 1) in Healthy Participants in the Pharmacokinetic Evaluable Population
Time Frame: Day 1, Week 12
|
Cohort 1: Blood samples for the assessment of plasma exenatide were collected at time = -15, 60, 90, 120, 180, 240, 360, and 480 minutes relative to study medication injection at time = 0 on Day 1 and the mean is presented below.
At all visits following the single injection, a single blood sample was collected for assessment of exenatide concentrations.
AUC was measured in picograms * hours per milliliter (pg*hr/mL).
Exenatide was measured using a validated enzyme-linked immunosorbent assay (ELISA).
AUC calculated using linear trapezoidal method from time x to time y; AUC (0-8h) and (0-tlast) are presented below.
Pharmacokinetic (PK) evaluable population consisted of all ITT participants who had at least 4 detectable plasma exenatide measurements [not less than (<) lower limits of quantification (LLOQ)] from Day 1 to Week 12 and had reliable PK data.
|
Day 1, Week 12
|
Maximum Concentration (Cmax) for Single Dose of 10 mg Exenatide (Cohort 1) in Healthy Participants in the Pharmacokinetic Evaluable Population
Time Frame: Day 1, Week 12
|
Cohort 1: Blood samples for the assessment of plasma exenatide were collected at time = -15, 60, 90, 120, 180, 240, 360, and 480 minutes relative to study medication injection at time = 0 on Day 1 and the mean is presented below.
At all visits following the single injection, a single blood sample was collected for assessment of exenatide concentrations.
Cmax was measured in picograms per milliliter (pg/mL).
Exenatide concentration was measured using a validated enzyme-linked immunosorbent assay (ELISA).
PK evaluable population consisted of all ITT participants who had at least 4 detectable plasma exenatide measurements [not less than (<) lower limits of quantification (LLOQ)] from Day 1 to Week 12 for the evaluation of the PK characteristics of plasma exenatide and had reliable PK data.
Cmax (0-8h) and (0-tlast) are presented below.
|
Day 1, Week 12
|
Time to Maximum Concentration (Tmax) for Single Dose of 10 mg Exenatide (Cohort 1) in Healthy Participants in the Pharmacokinetic Evaluable Population
Time Frame: Day 1, Week 12
|
Cohort 1: Blood samples for the assessment of plasma exenatide were collected at time(t) = -15, 60, 90, 120, 180, 240, 360, and 480 minutes relative to study medication injection at time = 0 on Day 1 an the mean is presented below.
At all visits following the single injection, a single blood sample was collected for assessment of exenatide concentrations.
Tmax was measured in hours and Tmax (0-8h) and (0-tlast) are presented below.
Exenatide concentration was measured using a validated enzyme-linked immunosorbent assay (ELISA).
PK evaluable population consisted of all ITT participants who had at least 4 detectable plasma exenatide measurements [not less than (<) lower limits of quantification (LLOQ)] and had reliable PK data.
|
Day 1, Week 12
|
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Injection Site TEAEs, Serious Adverse Events (SAEs), Deaths, and Withdrawals Due to AEs in Cohort 1 and Cohort 2 in Intent to Treat (ITT) Population
Time Frame: Day 1 to Week12
|
Treatment emergent (TE)=occurs during or after treatment with study drug.
Adverse Event (AE)=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment.
SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.
Participants experiencing multiple episodes of a given AE are counted once.
Injection site AEs: adverse events that existed prior to Day 1 and worsened after the first administration at Day 1, or occurred after the first administration at Day 1 through Week 12, or after Study Termination if considered by investigator to be clinically significant.
|
Day 1 to Week12
|
Number of Participants With Concomitant Medications in Cohort 1 and Cohort 2 in ITT Population
Time Frame: Day 1 to 12 weeks
|
Concomitant medications are defined as those medications received on or after the date of the first injection on Day 1, including prior medications that continued past Day 1 and new concomitant medications.
Participants may be counted in more than one medication class and no more than once in each class.
Categories by Anatomical Therapeutic Chemical (ATC) classification using the World Health Organization (WHO) Drug Dictionary version C1, 01 March 2009.
As per protocol, all participants in Cohort 1 could receive up to 2 anti-emetic medications approximately 30 minutes prior to the exenatide.
|
Day 1 to 12 weeks
|
Mean Change From Baseline to End of Study in Sitting Diastolic and Systolic Blood Pressure in Cohorts 1 and 2 in ITT Population
Time Frame: Day 1 to Week 12
|
In Cohort 1, sitting blood pressures were obtained at Screening (Visit 1), Day 1 (Visit 2), Weeks 1-11 (Visits 3-13), Week 12 (Visit 14), and at early termination.
Blood pressures (diastolic and systolic) were measured in millimeters of mercury (mmHg).
In Cohort 2, sitting blood pressures were obtained at Screening (Visit 1), Day 1 (Visit 2), Weeks 1-10 (Visits 3-12), Week 11 (Visit 15), Week 12 (Visit 16) and at early termination.
Baseline was defined as last measurement prior to first injection of study drug.
|
Day 1 to Week 12
|
Mean Change From Baseline to End of Study in Sitting Heart Rate in Cohorts 1 and 2 in ITT Population
Time Frame: Day 1 to Week 12
|
In Cohort 1, sitting heart rates were obtained at Screening (Visit 1), Day 1 (Visit 2), Weeks 1-11 (Visits 3-13), Week 12 (Visit 14), and at early termination.
Heart rate was measured in beats per minute (bpm).
In Cohort 2, sitting heart rates were obtained at Screening (Visit 1), Day 1 (Visit 2), Weeks 1-10 (Visits 3-12), Week 11 (Visit 15), Week 12 (Visit 16) and at early termination.
Baseline was defined as last measurement prior to first injection of study drug.
|
Day 1 to Week 12
|
Number of Participants With Hematology and Serum Chemistry Laboratory Values of Potential Clinical Importance in Cohorts 1 and 2 in ITT Population
Time Frame: Day 1 to Week 12
|
Abbreviations: Upper Limit of Normal (ULN); milligram per deciliter (mg/dL); units per liter (U/L); micro liters (µL); creatine kinase (CK); gamma-glutamyltransferase (G-GT).
Normal ranges = Hematocrit: 40.6-52.3%
(male), 35.3-47.0
(female); Platelets 155-361*10^3/µL(male/female); Calcium: 8.6-10.4
mg/dL (male/female); CK: 43-350 U/L (male), 28-207 U/L (female); G-GT: 7-62 U/L (male/female); Glucose 73-105 mg/dL (male/female); Lipase 14-70 U/L (male/female); Uric acid: 3.5-7.8
mg/dL (male), 2.3-5.9 mg/dL (female).
Blood samples for laboratories were collected at screening, Day 1, Weeks 4, 8, 12 or early termination.
Value for potential clinical importance is presented in each category presented below.
|
Day 1 to Week 12
|
Antibody Titers for Participants With Treatment Emergent Positive Antibodies to Exenatide in Participants Who Received Exenatide in Cohorts 1 and 2
Time Frame: Day 1 to Week 12
|
Serum titers of antibodies to exenatide were evaluated using a validated enzyme-linked immunosorbent assay (Covance Method No. ELISA-0308).
Positive antibody to exenatide titer: observed at the indicated visit following a negative or missing titer at baseline, or a positive titer that has increased by at least 3 dilutions at the indicated visit from a detectable baseline.
Baseline=Day 1. Negative titers were assigned a value of 1 in order to calculate geometric mean.
Geometric mean of reportable titers, by study week, are presented below.
|
Day 1 to Week 12
|
Area Under the Curve (AUC) for 2 mg Exenatide (Cohort 2) in Participants With Diabetes in the Pharmacokinetic Evaluable Population
Time Frame: Week 10-11; Weeks 10 - 12
|
Cohort 2: Blood samples for the assessment of plasma exenatide were collected on Day 1, Weeks 2, 4, 6, 8, and 10.
At Week 10, blood samples were collected at time = -15, 60, 90, 120, 180, 240, and 360 minutes relative to study medication injection at time = 0. AUC was measured in picograms * hours per milliliter (pg*hr/mL).
Exenatide was measured using a validated enzyme-linked immunosorbent assay (ELISA).
AUC calculated using linear trapezoidal method from time x to time y; AUC (0-6h) measured at Week 10, AUC (0-168h) steady state measured between Weeks 10 and 11, and AUC (0-tlast) for time interval between Weeks 10 and 12 (approximately336 hours) are presented below.
PK evaluable population consisted of all ITT participants who had at least 4 detectable plasma exenatide measurements (not < LLOQ) from Day 1 to Week 12 and had reliable PK data.
|
Week 10-11; Weeks 10 - 12
|
Average Exenatide Concentration (Cave) of 2 mg Exenatide (Cohort 2) in Participants With Diabetes in the Pharmacokinetic Evaluable Population
Time Frame: Week 10 - Week 11; Week 10 - Week 12
|
Cohort 2: Blood samples for the assessment of plasma exenatide were collected on Day 1, Weeks 2, 4, 6, 8, and 10.
At Week 10, blood samples were collected at time = -15, 60, 90, 120, 180, 240, and 360 minutes relative to study medication injection at time = 0.
At all visits following the single injection, a single blood sample was collected for assessment of exenatide concentrations.
Cave(0-168h) and Cave(0-tlast) was the time-weighted mean concentration over the sampling period from time x to time y corresponding to AUC (0-168h), and AUC (0-tlast), respectively.
Cave was measured in picograms per milliliter (pg/mL).
Exenatide concentration was measured using a validated enzyme-linked immunosorbent assay (ELISA).
PK evaluable population consisted of all ITT participants who had at least 4 detectable plasma exenatide measurements (not < LLOQ) from Day 1 to Week 12 and had reliable PK data.
|
Week 10 - Week 11; Week 10 - Week 12
|
Maximum Concentration (Cmax) for 2 mg Exenatide (Cohort 2) in Participants With Diabetes in the Pharmacokinetic Evaluable Population
Time Frame: Week 10, Weeks 10-11, Weeks 10-12
|
Cohort 2: Blood samples for the assessment of plasma exenatide were collected on Day 1, Weeks 2, 4, 6, 8, and 10.
At Week 10, blood samples were collected at time = -15, 60, 90, 120, 180, 240, and 360 minutes relative to study medication injection at time = 0. Cmax was measured in pg/mL.
Exenatide was measured using a validated enzyme-linked immunosorbent assay (ELISA).
Cmax summarized at 0-6 h at Week 10, 0-168 h at Weeks 10-11, and 0-tlast at Weeks 10-12.
PK evaluable population consisted of all ITT participants who had at least 4 detectable plasma exenatide measurements (not < LLOQ) from Day 1 to Week 12 and had reliable PK data.
|
Week 10, Weeks 10-11, Weeks 10-12
|
Time to Maximum Concentration (Tmax) of 2 mg Exenatide (Cohort 2) in Participants With Diabetes in Pharmacokinetic Evaluable Population
Time Frame: Week 10, Weeks 10-11, Weeks 10-12
|
Cohort 2: Blood samples for the assessment of plasma exenatide were collected on Day 1, Weeks 2, 4, 6, 8, and 10.
At Week 10, blood samples were collected at time = -15, 60, 90, 120, 180, 240, and 360 minutes relative to study medication injection at time = 0. Tmax was measured in hours (h).
Exenatide was measured using a validated ELISA.
Tmax summarized at 0-6 h at Week 10, 0-168 h at Weeks 10-11, and 0-tlast at Weeks 10-12.
PK evaluable population consisted of all ITT participants who had at least 4 detectable plasma exenatide measurements (not < LLOQ) from Day 1 to Week 12 and had reliable PK data.
|
Week 10, Weeks 10-11, Weeks 10-12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AUC (0 Hour to 168 Hour) for 10 mg Exenatide (Cohort 1) in Healthy Participants in the Pharmacokinetic Evaluable Population
Time Frame: Day 1 to Week 1
|
Cohort 1: Blood samples for the assessment of plasma exenatide were collected at time = -15, 60, 90, 120, 180, 240, 360, and 480 minutes relative to study medication injection at time = 0 on Day 1.
At all visits following the single injection, a single blood sample was collected for assessment of exenatide concentrations.
AUC (0-168 h) data represents average concentration rather than maximum concentration.
Exenatide concentration was measured using a validated enzyme-linked immunosorbent assay (ELISA).
AUC calculated using linear trapezoidal method from time x to time y and measured in pg*h/mL.
PK evaluable population consisted of all ITT participants who had at least 4 detectable plasma exenatide measurements (not < LLOQ) from Day 1 to Week 12 and had reliable PK data.
|
Day 1 to Week 1
|
Average Exenatide Concentration (Cave) of 10 mg Exenatide (Cohort 1) in Healthy Participants in the Pharmacokinetic Evaluable Population
Time Frame: Day 1 to Week 1
|
Cohort 1: Blood samples for the assessment of plasma exenatide were collected at time = -15, 60, 90, 120, 180, 240, 360, and 480 minutes relative to study medication injection at time = 0 on Day 1.
At all visits following the single dose, a single blood sample was collected for assessment of exenatide concentrations.
Cave(0-168h) was the time-weighted mean concentration over the sampling period from time x to time y corresponding to AUC (0-168h) and was measured in picograms per milliliter (pg/mL).
Exenatide concentration was measured using a validated enzyme-linked immunosorbent assay (ELISA).
PK evaluable population consisted of all ITT participants who had at least 4 detectable plasma exenatide measurements [not less than (<) lower limits of quantification (LLOQ)] from Day 1 to Week 12 and had reliable PK data.
|
Day 1 to Week 1
|
Least Square Mean Change From Baseline in Hemoglobin A1c (HbA1c) to Week 12 in Participants With Diabetes (Cohort 2) in the ITT Population
Time Frame: Day 1 to Week 12
|
HbA1c was measured as a percent of hemoglobin at screening, Day 1, Weeks 4, 8, 12 or early termination.
Last observation carried forward (LOCF) was applied to estimate missing values at post baseline timepoints.
Baseline=Day 1, last measurement prior to first dose of study drug.
|
Day 1 to Week 12
|
Number of Participants Achieving HbA1c Less Than Equal to (<=) 6.5% and Less Than (<) 7% at Week 12 in Participants With Diabetes (Cohort 2) in the ITT Population
Time Frame: Week 12
|
HbA1c was measured as a percent of hemoglobin at screening, Day 1, Weeks 4, 8, 12 or early termination.
LOCF was applied to estimate missing values at post baseline timepoints.
Baseline=Day 1, last measurement prior to first dose of study drug.
|
Week 12
|
Mean Change From Baseline at Week 12 in Body Weight in Participants With Diabetes (Cohort 2) in the ITT Population
Time Frame: Baseline, Week 12
|
Body weight was measured in kilograms (kg).
Baseline was Day 1, last measurement prior to first dose of study drug.
Body weight was measured at screening, Day 1, Weeks 4, 8, 12 or early termination and the LOCF approach was applied to estimate missing value at each post baseline timepoint.
|
Baseline, Week 12
|
Mean Change From Baseline at Week 12 in Fasting Plasma Glucose in Participants With Diabetes (Cohort 2) for the ITT Population
Time Frame: Baseline, Week 12
|
Baseline was the last measurement at the screening visit.
Fasting plasma glucose (FPG) was measured at screening, Day 1, Weeks 2, 4, 6, 8, 12, or early termination and reported in milligrams per deciliter (mg/dL).
|
Baseline, Week 12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Director: Vice President, Clinical Development, Amylin Pharmaceuticals, LLC.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2009
Primary Completion (ACTUAL)
August 1, 2009
Study Completion (ACTUAL)
August 1, 2009
Study Registration Dates
First Submitted
May 5, 2009
First Submitted That Met QC Criteria
May 6, 2009
First Posted (ESTIMATE)
May 7, 2009
Study Record Updates
Last Update Posted (ESTIMATE)
September 18, 2015
Last Update Submitted That Met QC Criteria
September 3, 2015
Last Verified
August 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BCB110
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
Clinical Trials on exenatide once weekly
-
AstraZenecaEli Lilly and CompanyCompletedType 2 DiabetesUnited States
-
AstraZenecaEli Lilly and CompanyCompletedType 2 Diabetes MellitusKorea, Republic of, China, Japan, Taiwan, India
-
AstraZenecaCompletedDiabetes Mellitus, Type 2United States
-
AstraZenecaEli Lilly and CompanyCompletedType 2 Diabetes MellitusUnited States
-
AstraZenecaEli Lilly and CompanyCompleted
-
AstraZenecaWithdrawn
-
AstraZenecaCompletedType 2 DiabetesUnited States
-
AstraZenecaCompletedComparison of the Effectiveness and Tolerability of Exenatide Once-weekly Compared to Basal InsulinsType 2 DiabetesUnited States
-
AstraZenecaCompletedType 2 Diabetes MellitusUnited States, Austria, Canada, Italy, Netherlands, Spain, United Kingdom, Taiwan, Thailand, Bulgaria, Belgium, Germany, Korea, Republic of, Hungary, Philippines, China, Malaysia, Hong Kong, New Zealand, Argentina, Czechia, Slovakia, Braz... and more
-
AstraZenecaCompletedChildren and Adolescent With Type 2 DiabetesUnited States, Hungary, Israel, Mexico, Bulgaria, Ukraine, Kuwait